Preclinical Development Of An Orexin Receptor Agonist For The Therapy Of Narcolepsy Type 1

Universities and Institutes of Italy

Italy

October 12, 2022

Description

  • Organisation/Company: ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA -
  • DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE
  • Research Field: Neurosciences › Neurophysiology
  • Researcher Profile: First Stage Researcher (R1) Recognised Researcher (R2) Established Researcher (R3) Leading Researcher (R4)
  • Application Deadline: 12/10/2022
  • Location: Italy
  • Type Of Contract: To be defined
  • The project will focus on the preclinical development of an orexin receptor agonist for the therapy of narcolepsy type 1, which is presently in the process of being patented by the host institution. The activities will include experiments in vivo with subcutaneous injection of the novel agonist in a validated mouse model of narcolepsy type 1 instrumented for sleep recordings, as well as experiments in vitro on cells expressing human orexin receptor 1 and 2 in order to quantify the agonist potency on either receptor.

    Eligibility criteria

    to apply for research grants fill out the form available at the following address: https: // bandi.unibo.it/ricerca/assegni-ricerca

    Eligible destination country/ies for fellows:

  • Italy
  • Eligibility of fellows: country/ies of residence:

  • All
  • Eligibility of fellows: nationality/ies:

  • All
  • Web site for additional job details

    https: // bandi.unibo.it/ricerca/assegni-ricerca

    Contact Information
  • Organisation/Company: ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA -
  • DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE
  • Organisation Type: Public Research Institution
  • Website: https:// www. unibo.it
  • Country: Italy
  • City: Bologna
  • Similar Jobs

    Add to favorites Read more...

    Mechanisms Of Complement Activation In Cancer: Role Of The Lectin Pathway

    lectin pathway in mouse models of cancer and metastasis using gene targeted lectin pathway activation and complement deposition using in vitro approaches; c) the relevance of this pathway through pharmacological targeting; d) its Eligible destination...

    Add to favorites Read more...

    Rif. 5379 - Innovative Approaches To Diagnosis, Monitoring And Treatment Of Lymphomas And Chronic...

    Research Field: Medical sciences Location: Italy › Bologna minimal residual disease after an effective treatment. bispecific antibodies in patients with heavily pretreated B-cell lymphomas; patients with hairy cell leukemia and correlation with overall survival and...